Hematologic Malignancies

18
Pipeline Programs
12
Companies
20
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
9
2
5
2
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
150%
Small Molecule
150%
+ 17 programs with unclassified modality

Competitive Landscape

12 companies ranked by most advanced pipeline stage

InnoCare
InnoCareChina - Beijing
1 program
1
ICP-248Phase 2/31 trial
Active Trials
NCT06378138Recruiting226Est. Jul 2031
Teva
TevaIsrael - Petach Tikva
1 program
1
StemEx®Phase 2/31 trial
Active Trials
NCT00469729Completed101Est. Jun 2015
Fate Therapeutics
Fate TherapeuticsSAN DIEGO, CA
4 programs
2
1
1
ProHema-CBPhase 21 trial
ProTmunePhase 1/21 trial
Biological: ProHema-CBPhase 11 trial
FludarabinePhase 11 trial
Active Trials
NCT02354417TerminatedEst. Feb 2017
NCT00890500CompletedEst. Oct 2013
NCT02743351CompletedEst. Nov 2021
+1 more trials
Pfizer
PfizerNEW YORK, NY
3 programs
2
1
extracorporeal photopheresisPhase 21 trial
PF-04449913Phase 11 trial
PF-0791800Phase 11 trial
Active Trials
NCT00953758Completed47Est. Feb 2013
NCT02663518Terminated249Est. Nov 2022
NCT00402714Completed14Est. Aug 2009
Takeda
TakedaTOKYO, Japan
1 program
1
Immune Globulin InfusionPhase 22 trials
Active Trials
NCT05952804Recruiting150Est. Jul 2028
NCT01485796Completed54Est. Jan 2013
Novartis
NovartisBASEL, Switzerland
1 program
1
ceritinibPhase 2Small Molecule1 trial
Active Trials
NCT02343679Withdrawn0Est. Oct 2022
M&
Merck & Co.RAHWAY, NJ
1 program
1
ridaforolimusPhase 21 trial
Active Trials
NCT00086125Completed57Est. Jun 2006
Sellas Life Sciences Group
1 program
1
SLS009Phase 1/21 trial
Active Trials
NCT04588922RecruitingEst. Dec 2025
Sanofi
SanofiPARIS, France
3 programs
3
CAMPATHPhase 11 trial
ClofarabinePhase 11 trial
clofarabinePhase 11 trial
Active Trials
NCT00113048Terminated24Est. Sep 2005
NCT00824135Completed34Est. Dec 2016
NCT00477542Completed18Est. Nov 2010
H
HutchmedChina - Hong Kong
1 program
1
HMPL-523Phase 11 trial
Active Trials
NCT02503033Unknown78Est. Mar 2021
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
mPEG-r-crisantaspasePhase 11 trial
Active Trials
NCT01551524Completed36Est. Feb 2015
Allogene Therapeutics
Allogene TherapeuticsSOUTH SAN FRANCISCO, CA
1 program
Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell ProductN/ACell Therapy1 trial
Active Trials
NCT06925685Enrolling By InvitationEst. Jan 2039

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
InnoCareICP-248
TakedaImmune Globulin Infusion
TevaStemEx®
TakedaImmune Globulin Infusion
Novartisceritinib
Fate TherapeuticsProHema-CB
Pfizerextracorporeal photopheresis
Merck & Co.ridaforolimus
Sellas Life Sciences GroupSLS009
Fate TherapeuticsProTmune
PfizerPF-0791800
HutchmedHMPL-523
Fate TherapeuticsBiological: ProHema-CB
Jazz PharmaceuticalsmPEG-r-crisantaspase
Fate TherapeuticsFludarabine

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 1,088 patients across 20 trials

NCT06378138InnoCareICP-248

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

Start: May 2024Est. completion: Jul 2031226 patients
Phase 2/3Recruiting
NCT01485796TakedaImmune Globulin Infusion

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Start: Dec 2011Est. completion: Jan 201354 patients
Phase 2/3Completed
NCT00469729TevaStemEx®

Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy

Start: Oct 2007Est. completion: Jun 2015101 patients
Phase 2/3Completed
NCT05952804TakedaImmune Globulin Infusion

IVIG for Infection Prevention After CAR-T-Cell Therapy

Start: Jun 2024Est. completion: Jul 2028150 patients
Phase 2Recruiting
NCT02343679Novartisceritinib

Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies

Start: May 2015Est. completion: Oct 20220
Phase 2Withdrawn
NCT01627314Fate TherapeuticsProHema-CB

The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.

Start: Jul 2012Est. completion: May 2017
Phase 2Terminated
NCT00402714Pfizerextracorporeal photopheresis

A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies

Start: Jul 2006Est. completion: Aug 200914 patients
Phase 2Completed
NCT00086125Merck & Co.ridaforolimus

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Start: Jun 2004Est. completion: Jun 200657 patients
Phase 2Completed
NCT04588922Sellas Life Sciences GroupSLS009

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies

Start: May 2021Est. completion: Dec 2025
Phase 1/2Recruiting
NCT02743351Fate TherapeuticsProTmune

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

Start: Dec 2016Est. completion: Nov 2021
Phase 1/2Completed
NCT02663518PfizerPF-0791800

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Start: Jan 2016Est. completion: Nov 2022249 patients
Phase 1Terminated
NCT02503033HutchmedHMPL-523

A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies

Start: Nov 2015Est. completion: Mar 202178 patients
Phase 1Unknown
NCT02354417Fate TherapeuticsBiological: ProHema-CB

A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies

Start: Dec 2014Est. completion: Feb 2017
Phase 1Terminated
NCT01551524Jazz PharmaceuticalsmPEG-r-crisantaspase

Phase I Study of mPEG-R-Crisantaspase Given IV

Start: Mar 2012Est. completion: Feb 201536 patients
Phase 1Completed
NCT00890500Fate TherapeuticsFludarabine

Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

Start: Jan 2011Est. completion: Oct 2013
Phase 1Completed
NCT00953758PfizerPF-04449913

A Study Of PF-04449913 In Select Hematologic Malignancies

Start: Mar 2010Est. completion: Feb 201347 patients
Phase 1Completed
NCT00824135SanofiClofarabine

Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies

Start: Jan 2009Est. completion: Dec 201634 patients
Phase 1Completed
NCT00477542Sanoficlofarabine

A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT

Start: May 2007Est. completion: Nov 201018 patients
Phase 1Completed
NCT00113048SanofiCAMPATH

Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies

Start: Dec 2003Est. completion: Sep 200524 patients
Phase 1Terminated
NCT06925685Allogene TherapeuticsFollow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product

Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product

Start: Jan 2025Est. completion: Jan 2039
N/AEnrolling By Invitation

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 1,088 patients
12 companies competing in this space